Team

Mark
Loughridge

Associate Director
Image
""

Mark is an Associate Director in the health and life sciences team. Prior to joining Global Counsel, Mark worked in public affairs and policy at the Royal College of Surgeons of England, covering issues including the UK’s future relationship with the EU, patient safety and addressing the COVID-related backlog in elective care. Prior to this, he worked in healthcare consulting, with a particular focus on specialised commissioning and rare disease policy.  

At GC, he works with corporates and investors from the health and life sciences sector to deliver strategic solutions to policy challenges.

Recent examples of his work include:

  • Advising clients in the logistics sector on the rapidly evolving NHS procurement landscape
  • Providing analysis to clients on the ramifications of new healthcare legislation, along with government strategy related to life sciences, health data and tech innovation
  • Supporting life sciences and health IT companies in their work to navigate the political environment and develop government advocacy strategies.

Latest Insights by Mark Loughridge

Health and Life Sciences icon

Are investor assumptions around NHS insourcing set to be challenged?

Health and Life Sciences

Structural and operational pressures – which have long been drivers for growth in the insourcing market – are here to stay, and any easing of these will occur from a high base. However, political scrutiny and pressure is growing and, in the context of the recent NHS Long Term Workforce Plan and a potential Labour government, this raises the risk of greater regulatory…

Read more
Health and Life Sciences icon

Global developments and the future of UK cancer screening

Health and Life Sciences

For patients given a timely cancer diagnosis, survival rates have never been better and, with revolutions in genomics and Artificial Intelligence (AI) gathering pace, the tide could soon turn comprehensively in favour of patients. However, the key to ensuring patients can benefit from this innovation is providing a comprehensive and accessible national screening service,…

Read more
Health and Life Sciences icon

Could payment system reform stifle NHS innovation and integration?

Health and Life Sciences

Amid a record-breaking elective backlog in England, NHS England has opted to flex its newly-granted financial powers by proposing a partial return to the Payment by Results system for acute care. But does this seemingly technical rewiring of the NHS’s financial flow have actual political and business salience? The answer is yes, and here is why. 

Read more
Health and Life Sciences icon

How exposed is the global health system to geopolitical tensions?

Health and Life Sciences

The COVID-19 pandemic has shone a light on the fragility of the public health systems that we take for granted. As the virulence of the pandemic begins to abate across much of the world, how exposed – or prepared – are counties for the impact of war, economic sanctions, political isolation and new migratory patterns on existing health structures and systems? 

Read more

View all Insights by Mark Loughridge